Lyell Immunopharma (NASDAQ:LYEL) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a sell rating to a hold rating in a report published on Sunday morning.

Several other brokerages also recently issued reports on LYEL. Citizens Jmp started coverage on Lyell Immunopharma in a report on Monday, March 9th. They set a “market outperform” rating and a $34.00 price target for the company. Robert W. Baird set a $49.00 price target on Lyell Immunopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Lyell Immunopharma in a report on Thursday. Finally, Zacks Research downgraded Lyell Immunopharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock opened at $19.33 on Friday. The business has a fifty day simple moving average of $22.19 and a two-hundred day simple moving average of $23.52. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00. The company has a market capitalization of $450.97 million, a price-to-earnings ratio of -1.40 and a beta of -0.05.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.10). Lyell Immunopharma had a negative return on equity of 84.36% and a negative net margin of 794,858.12%.The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts anticipate that Lyell Immunopharma will post -10.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lyell Immunopharma news, COO Stephen J. Hill sold 1,236 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total transaction of $28,910.04. Following the transaction, the chief operating officer owned 17,795 shares in the company, valued at $416,225.05. This trade represents a 6.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary K. Lee sold 1,671 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $23.39, for a total value of $39,084.69. Following the transaction, the insider owned 16,938 shares in the company, valued at $396,179.82. The trade was a 8.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 11,310 shares of company stock worth $264,285 in the last 90 days. Company insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LYEL. AQR Capital Management LLC increased its position in Lyell Immunopharma by 773.5% during the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after buying an additional 154,327 shares during the period. Acadian Asset Management LLC increased its position in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after buying an additional 443,614 shares during the period. Walleye Capital LLC bought a new position in Lyell Immunopharma during the 2nd quarter worth $258,000. Marshall Wace LLP bought a new position in Lyell Immunopharma during the 2nd quarter worth $94,000. Finally, Orbimed Advisors LLC bought a new position in Lyell Immunopharma during the 2nd quarter worth $457,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.